Pictet Asset Management Holding SA Has $1.77 Million Position in Medpace Holdings, Inc. $MEDP

Pictet Asset Management Holding SA lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 61.0% in the first quarter, HoldingsChannel.com reports. The fund owned 3,686 shares of the company’s stock after selling 5,757 shares during the period. Pictet Asset Management Holding SA’s holdings in Medpace were worth $1,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the fourth quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter worth approximately $30,000. Quarry LP bought a new stake in Medpace in the third quarter valued at approximately $35,000. Finally, Bayban bought a new stake in Medpace in the fourth quarter valued at approximately $44,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Medpace stock opened at $557.60 on Monday. Medpace Holdings, Inc. has a 12 month low of $306.70 and a 12 month high of $628.92. The stock’s 50 day moving average is $453.88 and its 200-day moving average is $496.19. The company has a market capitalization of $15.93 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.83 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. BMO Capital Markets reduced their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Royal Bank Of Canada decreased their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Finally, Robert W. Baird cut their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $467.08.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.